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ZEB1 is a master regulator of the Epithelial-to-Mesenchymal Transition (EMT) program.
While extensive evidence confirmed the importance of ZEB1 as an EMT transcription
factor that promotes tumor invasiveness and metastasis, little is known about its
regulation. In this work, we screened for potential regulatory links between ZEB1
and multiple cellular kinases. Exploratory in silico analysis aided by phospho-substrate
antibodies and ZEB1 deletion mutants led us to identify several potential phospho-sites
for the family of PKC kinases in the N-terminus of ZEB1. The analysis of breast
cancer cell lines panels with different degrees of aggressiveness, together with the
evaluation of a battery of kinase inhibitors, allowed us to expose a robust correlation
between ZEB1 and PKCα both at mRNA and protein levels. Subsequent validation
experiments using siRNAs against PKCα revealed that its knockdown leads to a
concomitant decrease in ZEB1 levels, while ZEB1 knockdown had no impact on PKCα
levels. Remarkably, PKCα-mediated downregulation of ZEB1 recapitulates the inhibition
of mesenchymal phenotypes, including inhibition in cell migration and invasiveness.
These findings were extended to an in vivo model, by demonstrating that the stable
knockdown of PKCα using lentiviral shRNAs markedly impaired the metastatic potential
of MDA-MB-231 breast cancer cells. Taken together, our findings unveil an unforeseen
regulatory pathway comprising PKCα and ZEB1 that promotes the activation of the EMT
in breast cancer cells.
Keywords: epithelial-to-mesenchymal transition, EMT, metastasis, breast cancer, triple negative, TNBC, PKCα,
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INTRODUCTION
Epithelial-to-mesenchymal transition (EMT) is an essential
program of normal embryonic development, tissue regeneration,
organ fibrosis and wound healing (1, 2). Activation of the EMT
program is also a critical step during metastatic expansion and
for the generation of tumor cells with stem cell properties
that play a major role in resistance to cancer treatment (3–
7). EMT is a highly dynamic process by which epithelial cells
undergo molecular changes that promote the acquisition of
a mesenchymal phenotype characterized by the disruption of
cell–cell adhesion, loss of cellular polarity, remodeling of the
cytoskeleton, and changes in cell–matrix adhesion, together
with enhanced migratory and invasive properties (1, 3–5, 8).
Several master regulatory programs have been discovered to
play key roles in cancer progression and EMT, which can be
activated by diverse signals, including TGF-β, Wnt, and TKR
(tyrosine kinase receptor) ligands. These external signals regulate
transcription factors (TFs) such as ZEB1, SNAIL, and TWIST
by integrating molecular mechanisms which are still not fully
understood (1, 3, 4, 8, 9).
Several studies showed that ZEB1 (Zinc Finger E-box Binding
Homeobox 1) has an active role in the induction of EMT in
diverse epithelial malignancies, such as colon, prostate, pancreas,
lung and breast cancer (10–15). Notably, the expression of ZEB1
in these tumors correlates with the loss of E-cadherin and is
associated with advanced or metastatic disease, by triggering
combined activation of cell motility and stemness properties (10,
16–18). However, there is still insufficient information regarding
the signaling mechanisms that regulate ZEB1 during the EMT
program. The regulation and function of ZEB1 in a physiological
context has been widely studied (19–25).
Numerous investigations of recent years were focused
in understanding the regulation of ZEB1 at different levels
(transcriptional, translational, and post-translational). At
transcriptional level, it has been reported that ZEB1 mRNA
levels could be regulated by numerous TFs, among which
SNAIL 1 and TWIST stand out because of their well-established
participation in the regulation of the EMT program (26, 27). On
a related note, numerous reports unveiled a role for miR-200
family members in the control of the epithelial phenotype
through the regulation of ZEB transcription factors (ZEB1
and ZEB2). Interestingly, all miR-200 family members are
direct transcriptional targets of ZEB1 and ZEB2, thus defining
a double-negative feedback loop that control their mutual
expression concomitantly with EMT progression (18, 28–32).
At post-translational level, we have reported that changes in the
phosphorylation status of ZEB1 modifies its binding to target
promoters and ZEB1 transcriptional activity (33). In line with
this, other research groups have shown that ZEB1 is a key TF
during EMT induced by the TGF-β (34, 35). In addition, it has
been reported that the IGF1 pathway is able to inducing and
regulating the EMT program by regulation of ZEB1 levels in
breast, prostate, endometrial and ovarian cancer, among others
(11, 12, 36–38). Nonetheless, the molecular details and the
regulatory players that orchestrate ZEB1 functionality during the
EMT remain poorly understood today (39–44).
PKC isozymes play major roles in the control of signaling
pathways associated with proliferation, migration, invasion,
tumorigenesis, and metastasis, and have been associated with
EMT (45–51). Based on their biochemical and structural
properties, PKCs have been classified into three families:
classical/conventional or calcium-dependent PKCs (cPKCs α,
βI, βII, and γ), novel or calcium-independent PKCs (nPKCs
δ, ε, ņ, and θ); and atypical PKCs (aPKCs ζ and ι). Despite
their high homology and similar substrate specificity in vitro,
PKC isozymes possess distinctive functional selectivity in cellular
models due to their differential intracellular localization and
access to substrates (46, 52–55). Changes in the expression
levels or activation status of PKC isozymes have been reported
in numerous human cancers, and in many cases correlations
have been described between high levels of PKCs and degree of
aggressiveness (47, 56, 57).
In this work, we unveiled an unforeseen role of PKCα in the
upregulation of ZEB1 levels in breast cancer cells. Moreover, we
also investigate the contribution of this PKCα/ZEB1 axis into the
establishment and maintenance of the mesenchymal state and
how PKCα-dependent modulation of ZEB1 levels controls tumor
aggressiveness and metastasis using in vitro and in vivomodels.
MATERIALS AND METHODS
Cell Lines and Cell Culture
Cells used in this study were obtained from ATCC. MCF-
10A cells were cultured in Dulbecco’s Modified Eagle
Medium/Nutrient Mixture F-12 (DMEM/F-12) (Thermo
Scientific) supplemented with 5% equine serum (GIBCO), 1%
penicillin-streptomycin (GIBCO), 20 ng/ml EGF (Sigma-
Aldrich), 10µg/ml insulin (Sigma-Aldrich), 0.5 mg/ml
hydrocortisone (Sigma-Aldrich) and 100 ng/ml cholera
toxin (Calbiochem). MCF-7 and T47-D cells were cultured
in RPMI (GIBCO) supplemented with 10% fetal bovine serum
(FBS; GIBCO), 1% L-glutamine (GIBCO) and 1% penicillin-
streptomycin (GIBCO). NMuMG-NZEB1 and NMuMG-Vector
cell lines were cultured in DMEM supplemented with 10%
FBS, 1% L-glutamine, and 400µg/ml G418 (Sigma-Aldrich).
Other cell lines (HEK-293T; BT-549; MDA-MB-231; MDA-
MB-468; SKBR-3; MDA-MB-361 and BT-474) were cultured
in DMEM supplemented with 10% FBS and 1% penicillin-
streptomycin. All the cell lines used in this work were negative
for mycoplasma contamination.
Stable Cell Lines Generation
NMuMG epithelial cells were transfected with eGFP-NZEB1
or eGFP-C3 empty vector (EV), using lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions,
followed by 10 days selection with geneticin (G418, Sigma-
Aldrich). Two rounds of cell sorting for GFP-positive cells
were performed after antibiotic selection (FACS Aria II, BD
Bioscience). Stable knockdown of PKCα in MDA-MB-231
cells was achieved by transduction using the PLKO system
of lentiviral shRNA-PKCα (Dharmacon) or shRNA-NTC as
a control. Selection of stable cell lines was carried out with
puromycin (2µg/ml, Santa Cruz) for 10 days.
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DNA Constructs, shRNA, and RNAi
The full-length rat ZEB1 cDNA (21) was subcloned into
pcDNA4/HisMaxB (Invitrogen) (ZEB1-FL). ZEB1 deletion
mutants ZD1-HD and eGFP-NZEB1 were subcloned by into
pcDNAI/Amp vector (Invitrogen) or eGFP-C3 (Clontech),
respectively. Full-length ZEB1 and ZEB1 deletion mutants were
a kind gift from Dr. Douglas S. Darling (University of Louisville,
USA). The E-cadherin luciferase promoter was a kind gift from
Dr. Frans Van Roy (University of Ghent, Belgium) (58). All
constructs were verified by sequencing.
RNAi duplexes were purchased from Dharmacon (PKCα1:
CCAUCCGCUCCACACUAAA; PKCα2: GAACAACAAGGA
AUGACUU; PKCα3: UAAGGAACCACAAGCAGUA; PKCα4:
UUAUAGGGAUCUGAAGUUA; PKCα5: GAAGGGUUCUCG
UAUGUCA; PKCα6: UCACUGCUCUAUGGACUUA; ZEB1#1:
CUGUAAGAGAGAAGCGGAA; ZEB1#2: CUGAAAUCCUCU
CGAAUGA; ZEB1#3: GCGCAAUAACGUUACAAAU; ZEB1#4
GCAACAGGGAGAAUUAUUA; NTC: UGGUUUACAUGU
UUUCUGA).
shRNAs were purchased from Dharmacon (PKCα: α1
TRCN1691; α2 TRCN1692; α3 TRCN1693) (ZEB1: Z1
TRCN17563; Z2 TRCN17565; Z3 TRCN17566), shNTC-pLKO.1
was obtained from Addgene (ID#1864).
Transfections and Lentiviral Infection
RNAi duplexes (25 nM) were transfected using Lipofectamine
RNAiMAX (Thermo Fisher Scientific). HEK-293T cells were
transfected to obtain virus particles using JetPrime (Polyplus-
transfection) as recommended by the manufacturer. Stable
knockdown of PKCα in MDA-MB-231 was achieved by
transduction using the PLKO system of lentiviral shRNA-PKCα
(Dharmacon) or shRNA-NTC as a control according to the
manufacturer’s protocol.
In silico Analysis
Prediction of potential ZEB1 phosphorylation sites was
performed using by DISPHOS 1.3 KinasePhos and NetPhos 3.1
open source Web search tools (59–61).
Luciferase Reporter Assays
HEK-293T cells (5 × 104) were transfected by lipofection using
PEI (PolyEthylenImine, Polysciences Inc.) (62). We used 0.3 µg
of E-cadherin-Luc promoter and 0.3 µg of CMVβ clone (β-
galactosidase reporter vector, Clontech) for normalization, which
were co-transfected together with 0.5 µg of ZEB1-FL or each
ZEB1 deletion mutant (ZD1-HD or NZEB1). Luciferase and β-
galactosidase activities were evaluated as described (22). Results
were expressed as the percentage of luciferase activity relative to
the activity of the promoter with the empty vector (EV) (100%),
normalized in each case to β-galactosidase activity.
Treatment of Cells With Pharmacological
Inhibitors
Cells were treated at the indicated times with the following
inhibitors: GSK3 inhibitor LiCl (50mM), Akt inhibitor LY294002
(20µM, Calbiochem), MEK1/2 inhibitors PD98059 (20µM,
Calbiochem) and UO126, or its corresponding control UO124
(20µM, Calbiochem), pan-PKCs inhibitor GF109203X (5µM,
Enzo Life Sciences) and Gö6983 (5µM, Enzo Life Sciences), or
the protein synthesis inhibitor cycloheximide (CHX, 25µg/ml,
Calbiochem). DMSO (Sigma-Aldrich) was used as vehicle and
never exceeded a final concentration of 0.1%.
Protein Analysis
Western blot analysis (WB) was carried out essentially as
previously described in (63). The detection and quantification
were performed with Odyssey Clx System (LI-COR Biosciences)
through the Image Studio Software, or by traditional ECL
detection. The following antibodies were used: anti-ZEB1-1642
(from Dr. Douglas Darling Lab), anti-ZEB1 (Santa Cruz,#
sc-25388), anti-E-cadherin (BD Biosciences,# 610182), anti-
vimentin (Cell Signaling, #5741), anti-SNAIL (Cell Signaling,
#3879), anti β-catenin (Cell Signaling, #8480), anti ZO-1
(Cell Signaling, #8193), anti-cytokeratin 18 (Cell Signaling,
#4548), anti-phospho serine/threonine (Abcam, #ab9337), anti-
phospho-substrates antibodies kit Cell Signaling, #9920) anti-
GFP (Abcam, #ab290), anti-PKCα (Santa Cruz, # sc-208), anti-
PKCδ (Cell Signaling, #2058) anti-PKCε (Santa Cruz,# sc-1681),
anti- Phospho-PKCα/β II (Cell Signaling, #9375) anti-α-tubulin
(Sigma-Aldrich, #T5168); anti-β-actin (Sigma-Aldrich, #A2228);
anti-PCNA (Santa Cruz, #sc56). As secondary antibodies we
used anti-rabbit-Alexa-Fluor 594 (Molecular Probes), anti-rabbit
HRP (Cell Signaling, #7074), anti-mouse HRP (Cell Signaling,
#7076), goat anti-mouse IRDye 680RD and goat anti-rabbit
IRDye 800CW (LI-COR Biosciences).
Immunoprecipitation (IP)
HEK-293T cells were transfected with either ZD1-HD or NZEB1,
or the corresponding empty vectors (pcDNA1 or eGFP). After
48 h, cells were lysed in RIPA buffer. Cell extracts were subject to
IP using either anti-ZEB1-1642 (from Dr. Douglas Darling Lab)
or anti-GFP (Abcam, #ab290). An anti-IgG antibody was used as
control. IP assays were performed using the Classic IP kit (Pierce)
according to the manufacturer’s instructions. Eluted immune-
complexes were run in 10% SDS-PAGE gels and Western blot
analysis was performed using the indicated antibodies.
Pull-Down With Ni2+ Beads
HEK-293T cells were co-transfected with His6-ZEB1 (HM-
ZEB1) and untagged PKCα for 48 hs. Before pull-down, cells
were pretreated with PMA 10 nM for 15min. The purification
was carried out under non-denaturing conditions. The pull-
down assay was performed using Ni-NTA Agarose (QIAGEN)
according to the manufacturer’s instructions. Eluted immune-
complexes were resolved in 10% SDS-PAGE gels and Western
Blot were performed using the indicated antibodies.
Real-Time Quantitative PCR (RT-qPCR)
Total RNA from cells was isolated using the RNeasy Mini Kit
(Qiagen). One µg of total RNA was reverse transcribed to
cDNA with the TaqMan Reverse Transcription Kit (Invitrogen).
qPCR was performed in a ABI PRISM 7700 detection system
using TaqMan Universal PCR MasterMix (Applied Biosystems),
target primers (900 nM), fluorescent probe (250 nM) and cDNA.
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TaqMan probes specific for PKCα, ZEB1, E-cadherin, vimentin
and the housekeeping gene UBC (used for normalization) were
purchased from Applied Biosystems (ZEB1: ZEB1-FAMTM dye
Hs01566408_m1; PKCα: PRKCA-FAMTM dye Hs00925195_m1;
vimentin: Vimentin-6FAMTM dye Hs00185584_m; E-cadherin:
E-cad-6FAMTM dye Hs01023894_m1; UBC: UBC-VICTM dye
Hs00824723_m1). PCR product formation was continuously
monitored using the Sequence Detection System software version
1.7. Results were expressed as fold-change of the target gene by
the 2-11Ct method and normalized to the NTC sample. All
qPCR reactions were performed in triplicate. Every experiment
was independently performed three times.
Immunostaining and Confocal Microscopy
Cells growing on glass coverslides were fixed with 4%
paraformaldehyde, stained with an anti-E-cadherin antibody
anti-E-cadherin (BD Biosciences, # 610182) or rhodamine-
phalloidin (Molecular Probes), and nuclei counterstained
with DAPI (0.3µg/ml, Sigma-Aldrich). Confocal images were
taken with an Olympus FluoView FV1000 Laser Scanning
confocal microscope.
Wound Healing Assay
Cells were grown to full confluence in 6-well plates in DMEMand
reduced serum supplementation (1%). Subsequently, a wound
was made using a pipette tip, and the plate was washed twice
with media to remove detached cells. Photomicrographs of initial
wounds (t:0) and final wounds after 16 or 24 h (t:16 or t:24)
were captured using an optical microscope equipped with a
motorized stage (Leica DMI 8). The initial and final wound
areas were measured using the ImageJ/Fiji software, and the
difference between the two was used to determine migrated area.
Experiments were done in triplicate, and every experiment was
performed independently three times.
Invasion Assay
Cells were trypsinized, suspended in 0.1% BSA/DMEM, and
seeded (2.5 × 104 cells/well) in the upper compartment of a
Boyden chamber (NeuroProbe). Matrigel-coated polycarbonate
membranes (8-µm pore diameter) were used to separate the
upper and lower compartments. In the lower chamber, DMEM
medium containing 10% FBS was used. After an incubation
period of 16 or 24 h at 37◦C, membranes were recovered
and cells on the upper side of the membrane (non-invasive)
were wiped off the surface. Cells on the lower side of the
membrane (invasive) were fixed and stained with the Hema 3
Staining kit (Thermo Scientific). Invasive cells in each well were
counted in five random fields by contrast microscopy using an
optical microscope equipped with a motorized stage (Leica DMI
8) and the ImageJ/Fiji software. Each condition was assessed
by triplicate. Every experiment was performed independently
three times.
Soft Agar Colony Formation Assay
The soft agar colony formation assay in NMuMG cells (NZEB1
or EV) was carried out as a previously described in (64).
Ten independent fields were photographed using an optical
microscope (NIKON ECLIPSE TE2000-U). The quantification
of the number of colonies formed by more than 20 cells was
performed. Each condition was assessed by triplicate. Every
experiment was performed independently three times.
In vivo Experimental Metastasis Assay
All animal experimental protocols were approved by the Ethical
Committee on Animal Care and Use (CICUAL 63/2016),
University of Buenos Aires (Argentina), and experiments
performed in compliance with the ARRIVE Animal Research
guidelines recommendations. Six to eight-week-old NOD/SCID
male mice were inoculated with 27G needles containing 1 ×
106 cells through tail vein injection. Animals were housed with
access to food and water ad libitum in ventilated mouse cages (1–
5 mice per cage) at the IBioBA Institute Animal Services Facility
and were randomly divided into the different treatment groups.
Seventy-five days after injection, animals were euthanized and
their lungs were carefully inflated with a neutralized buffered
formalin (NBF) solution containing 40% formalin, 4 g/liter
NaH2PO4, and 6.5 g/liter Na2HPO4. Lungs were then removed
and collected into NBF containing tubes to enable 24 h fixation
at room temperature. Tissues were then washed and stored in a
70% ethanol solution.
Metastatic Foci Analysis
Lung tissue DNA sample preparation for metastatic foci
analysis was performed with Qiagen DNeasy R© Blood &
Tissue kit, following the manufacturer’s instructions. qPCR
was performed to determine the relative abundance of
human DNA in mice tissues. The amplification reactions
of 40 cycles were carried out with specific primers for
human GAPDH (Fw: 5′ TCGACAGTCAGCCGCATCTTCT
3′, Rv: 5′ GAACACATCCGGCCTGCGC 3′) and mouse
GAPDH (Fw: 5′ ATGCCACCGACCCCGAGGAA 3′, Rv: 5′
CCTGGCGATGGCTCGCACTT 3′) using FastStart Essential
DNA Green Master Mix from Roche. Data were analyzed with
Bio-Rad CFX M. For each sample, the values were normalized
to mouse GAPDH levels. The Human GAPDH /Mouse GAPDH
ratio was used to quantify the incidence of metastasis.
In silico Analysis of PRKCA and ZEB1
mRNA Expression Among Breast Cancer
Cell Lines
Pre-processed PRKCA and ZEB1 mRNA expression levels and
intrinsic subtypes among 54 breast cancer cell lines were obtained
from the Heiser 2012 dataset (E-MTAB-181) at UCSC Xena
browser (https://xenabrowser.net/). Univariate and bivariate
Pearson’s test was employed for correlation analysis between both
genes using R software.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 6.0
(GraphPad Software), applying two-tailed Student’s t-test or
analysis of variance (ANOVA) test as appropriate. A p < 0.05
was considered statistically significant. Statistical probability is
expressed as ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.
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RESULTS
A Small N-Terminal Fragment of ZEB1 That
Retains Its Capacity to Promote the EMT Is
a PKC Substrate
While changes in the phosphorylation status of ZEB1 are known
to affect its binding to gene promoters and transcriptional
activity, the kinases responsible for ZEB1 phosphorylation
have not been yet described. As a first approach to identify
putative ZEB1 kinases in cancer cells, we performed an in-
silico screening of phosphorylation sites for multiple central
kinases, including PKCs, PKA, MAPKs, and AKT. For this
analysis, we used DISPHOS 1.3 KinasePhos and NetPhos 3.1
open source web search tools, which revealed a large number
of potential phosphorylation sites in ZEB1. Even focusing on
those sites that display high scores, there were a plethora of
putative sites distributed in all ZEB1 functional domains (ZD1,
HD, and ZD2) and across the rest of the protein, as highlighted
in Figure 1A. Due to this level of complexity, we concluded
that a classical site-directed mutagenesis would be an unsuitable
experimental strategy to identify novel regulatory kinases for
ZEB1. Thus, we decided to follow up the analysis by using
ZEB1 deletion mutants (ZD1-HD and NZEB1). These constructs
represent 60% and 10% of the full-length protein, respectively,
and both retain the capacity to repress the E-cadherin promoter
in cells, as determined with a luciferase reporter assay in
cells (Figure 1B). To explore the involvement of regulatory
kinases identified in the in-silico screening, we analyzed the
phosphorylation of ZEB1 using a panel of commercial phospho-
substrate antibodies against consensus sites of various kinases,
namely MEK/ERK, PKC, AKT, and PKA, as well as with an
anti-phospho serine/threonine antibody. Immunoprecipitation
experiments were performed in HEK-293T cells and, as expected
from the in-silico analysis, we found that ZEB1 is a substrate of
multiple kinases in cells (Figure 1C).
A closer look to the NZEB1 sequence revealed a remarkable
enrichment in phospho-sites for PKCs (Figure 1A). To
determine if NZEB1 can be indeed phosphorylated by PKC in
cells, we expressed it as a GFP-fused protein in HEK-293T cells,
and immunoprecipitated the protein with an anti-GFP antibody.
Notably, using an anti-PKC phospho-substrate antibody, we
found significant immunoreactivity in the immunoprecipitates
against GFP-NZEB1 but not against GFP alone (Figure 1D).
Based on these preliminary findings, we decided to focus our
study on a potential regulatory link between ZEB1 and PKC.
Next, we wished to confirm that GFP-NZEB1 represented
a suitable model to study the regulation of ZEB1. Toward
this goal, we investigated if GFP-NZEB1 recapitulates the
phenotypes observed during the activation of the EMT program,
as normally observed with the full-length protein. A stable
cell line expressing GFP-NZEB1 was derived from NMuMG
mammary epithelial cells (Supplementary Figure 1A). We
evaluated the levels of several EMT markers (Figure 1E and
Supplementary Figure 1B). We found that stable expression
of GFP-NZEB1 repressed the expression of epithelial hallmark
E-cadherin (Figure 1E and Supplementary Figure 1C), affecting
also the expression and subcellular localization of β-catenin
(Supplementary Figures 1B,D) and increasing the expression of
the mesenchymal marker Vimentin (Supplementary Figure 1B).
These changes in the expression of EMT markers correlated
with the loss of the epithelial phenotype and the acquisition
of mesenchymal traits (Supplementary Figure 1E), which
are characterized by a dramatic change in the cell-cell
interactions, overall cellular shape, and the reorganization
of the cortical actin cytoskeleton (Figure 1F). Moreover,
the acquisition of the mesenchymal phenotype was
accompanied by increased migratory capacity (Wound healing—
Supplementary Figure 1F), invasiveness (Matrigel invasion
assay—Figure 1G) and anchorage-independent cell growth (Soft
agar colony formation—Supplementary Figure 1G).
PKCα Levels and Activity Correlate With
ZEB1 Levels in Breast Cancer Cells
Based on our previous results, we investigated a potential
functional regulation of ZEB1 by PKC. NMuMG cells stably
expressing NZEB1 were treated with the pan-PKC inhibitors
GF109203X or Gö6983. Interestingly, WB analysis revealed that
NZEB1 levels decreased in response to both PKC inhibitors,
whose activities were confirmed by a reduced phosphorylation
of PKCα/βII (Figure 2A). On the other hand, no effect on
ZEB1 expression could be detected when cells were treated
with the GSK3 inhibitor LiCl, the PI3K inhibitor LY294002,
or the MEK1/2 inhibitors PD98059 and UO126. These results
uncover a specific role of PKC in the modulation of ZEB1
protein expression levels, and are consistent with the lack of
relevant phosphorylation sites for GSK, Akt, and MEK/Erk
within NZEB1 (Figure 2B).
To explore in more detail the link between PKC and ZEB1,
we investigated a panel of breast cancer cells of different subtypes
(luminal and basal-like) and different degrees of aggressiveness.
We found that basal-like breast cancer cell lines express high
ZEB1 levels (particularly MDA-MB-231 and BT-549 cells). These
cells also express high levels of PKCα and display mesenchymal
features (low E-cadherin, high vimentin). On the other hand,
luminal cells generally express low ZEB1 levels, and in most
cases display lower expression of PKCα compared to basal-like
breast cancer cells (with the exception of MDA-MB-453 cells
(Figure 2C). Indeed, a positive correlation between ZEB1 and
PKCα expression levels was found for the different breast cancer
cell lines used in this analysis (r = 0.82, p < 0.001) (Figure 2D).
Such correlation was not observed for other PKC isozymes
known to have important roles in breast cancer progression,
namely PKCδ and PKCε (45) (Supplementary Figures 2A,B).
To expand on this finding, we bioinformatically explored the
Heiser 2012 dataset (E-MTAB-181), where we cross-examined
the mRNA levels of ZEB1 and PKCα in a larger panel of breast
cancer cell lines. This analysis also revealed a significant positive
correlation between ZEB1 and PKCα protein expression levels,
not only for the cell lines described in Figure 2D but also for the
entire panel comprising 54 breast cancer cell lines (r = 0.72, p <
0.001) (Figure 2E). These results strongly suggest a link between
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FIGURE 1 | An N-terminal fragment of ZEB1 which retains its EMT-inducing capacity is a phospho-substrate of PKCs. (A) Scheme of the in-silico analysis of ZEB1
potential phosphorylation sites. (B) Left: schematic representation of ZEB1 full-length (ZEB1-FL) and the deletion mutants used: ZD1-HD and NZEB1 (ZD1: N-terminal
zinc finger cluster, HD: Homeodomain, and ZD2: C-terminal zinc finger cluster). Right: Luciferase reporter assay of the E-cadherin promoter activity in HEK-293T cells
co-transfected with either ZEB1-FL or ZEB1 deletion mutants. (C,D) Immunoprecipitation of ZD1-HD or NZEB1. Western blots were performed using a specific set of
anti-phospho substrates antibodies for MEK/ERK (p-S MEK/ERK-Sub), PKCs (p-S PKC-Sub), PKA (p-S/T PKA-Sub) and AKT (p-S/T AKT-Sub) kinases; anti-phospho
serine/threonine (p-S/T), anti-ZEB1 or anti-GFP. (E) Western blots for endogenous ZEB1, NZEB1 and E-cadherin in NMuMG epithelial cells stably expressing NZEB1
or GFP-Empty Vector (EV). (F) Confocal microscopy analysis of F-actin cytoskeleton distribution determined by rodamine-phalloidin staining (white) in stable NZEB1 or
EV NMuMG cell lines. Nuclei were stained with DAPI (blue). Magnification: 60X; Bar: 10µm. Red and white arrows indicate lamellipodia and filopodia, respectively.
(G) Matrigel invasion assay in NZEB1 or EV NMuMG cells. Magnification: 10X. Bar: 50µm. Results are expressed as mean ± S.D>. ns, not significant, *p ≤ 0.05, ***p
≤ 0.001).
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FIGURE 2 | PKCα levels and activity correlate with ZEB1 levels in breast cancer cells. Western blot analysis of NZEB1 levels in NMuMG-NZEB1 cells (A) treated with
the pan-PKC inhibitors GF109203X (GF ) or GÖ6983 (GÖ) (5µM) for the indicated times; or (B) treated with specific inhibitors of several signal transduction pathways:
GSK3 inhibitor LiCl (50mM), AKT inhibitor LY294002 (LY, 20µM), MEK1/2 inhibitors PD98059 (PD, 20µM) and UO126 and its respective negative control UO124
(20µM), pan-PKCs inhibitor GF109203X (GF, 5µM) or DMSO (vehicle) for 48 h. Graphs represent protein levels of NZEB1 (fold-change), normalized to the loading
control and relativized to time 0 h in (A), or to DMSO (vehicle) in (B). Results are expressed as mean ± S.D. **p ≤ 0.01; ***p ≤ 0.001). (C) Western blot analysis of
ZEB1, PKCα, PKCε, PKCδ, and EMT markers (E-cadherin and vimentin) in breast cancer cells. (D) Analysis of protein expression levels of PKCα and ZEB1 in the
entire set of breast cancer cell lines. Pearson r = 0.82. ***p ≤ 0.001. (E) In silico analysis of PKCα and ZEB1 mRNA expression among 54 breast cancer cell lines in
the Heiser 2012 dataset. Pearson r = 0.72. ***p ≤ 0.001).
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PKCα activity and ZEB1 that potentially contributes to EMT in
breast cancer cells.
PKCα Knockdown Reduces Endogenous
ZEB1 Levels in Breast Cancer Cells
The observed correlation between PKCα and ZEB1 in breast
cancer cell lines prompted us to explore a direct link between
them in more detail. We focused on MDA-MB-231 breast
cancer cells, a model that shows high levels of expression
of ZEB1 and PKCα, and in which ZEB1 function has been
extensively studied (48, 65, 66). To determine whether a
causal relationship exists between PKCα and ZEB1 expression
levels, we silenced PKCα using RNAi. Two different duplexes
(α1 and α2) were used, which reduced PKCα mRNA levels
by >95% and PKCα protein levels by >80% at 72 h post-
transfection (Figure 3A). Interestingly, upon PKCα silencing,
endogenous ZEB1 mRNA and protein levels were significantly
reduced (Figure 3A). In the time-frame of these experiments, the
observed ZEB1 down-regulation was not sufficient to trigger a
detectable induction in E-cadherin protein levels, yet a significant
increase in E-cadherin mRNA levels was observed, consistent
with a reversion of the mesenchymal phenotype taking place
(Figure 3A). These results were validated using 4 additional
siRNAs sequences for PKCα (Supplementary Figure 3A), as well
as by pharmacological inhibition with GF109203X or Gö6983
(Supplementary Figure 3B). Moreover, ZEB1 protein levels were
also consistently reduced in MDA-MB-453 and BT-549 cells
upon PKCα silencing, although ZEB1 mRNA decrease in these
cell lines was not as substantial as the one observed in MDA-M-
231 cells (Figure 3B).
Data from Figure 3, together with the experiments shown in
Figure 2 with NZEB1 (which is expressed from an exogenous
promoter), suggest that ZEB1 might be downregulated both at
mRNA and protein levels upon PKCα silencing. To explore this
scenario, we performed experiments using the protein synthesis
inhibitor cycloheximide (CHX) and examined ZEB1 half-life.
Cell were transfected with PKCα RNAi duplexes and 60 h later
treated with CHX for 12 or 16 h. We found that CHX-treated
cells have reduced ZEB1 protein levels when PKCα was inhibited
(Supplementary Figure 3C). A similar result was observed when
PKC was pharmacologically inhibited by GF109203X for 48 h
(Supplementary Figure 3C). Together, these findings suggest
the co-existence of transcriptional and post-transcriptional
mechanisms that promote ZEB1 downregulation in response to
PKCα inhibition.
To explore the hierarchy within the PKCα/ZEB1 axis, we
analyzed the expression of PKCα in MDA-MB-231 cells after
ZEB1 silencing. In this scenario, we found no evidence of
changes in the expression of PKCα or other PKCs isozymes
in ZEB1-KD cells. Note that at 72 h post-transfection, there
is no E-cadherin protein up-regulation (despite elevation in
E-cadherin mRNA levels) or changes in vimentin expression
(Figure 3C). However, an elevation in E-cadherin protein levels
becomes obvious at 96 h, and using 4 different ZEB1 RNAi
sequences (Supplementary Figure 3D). Thus, while PKCα has
an important upstream role in regulating ZEB1 levels, ZEB1 does
not control the expression of PKCα. Interestingly, by performing
immunoprecipitation experiments of exogenous ZEB1 we were
able to pull-down PKCα (Supplementary Figure 3E), which
further supports a mechanism of direct regulation of ZEB1
stability by PKCα phosphorylation.
PKCα Knockdown Recapitulates EMT
Inhibition and Modulates the Metastatic
Potential of Breast Cancer Cells in vivo
An immediate question that arose from exposing the link
between PKCα and ZEB1 levels was if PKCα downregulation
is sufficient to recapitulate the reversion of the mesenchymal
phenotype observed after ZEB1 knockdown. Given the relevance
of ZEB1 in cancer progression, we were particularly interested
in exploring if the migratory and invasive capacities of breast
cancer cells were altered upon PKCα RNAi depletion, similar to
when ZEB1 is down-regulated (Supplementary Figures 4A,B).
Notably, we found that the migratory capacity of MDA-MB-
231 cells was markedly reduced either upon PKCα silencing or
GF10923X treatment, as determined using a wound healing assay
(Figure 4A). Likewise, when we used the Matrigel invasion assay,
we unveiled also an important reduction in the invasive capacity
of cells subjected to PKCα knockdown (Figure 4B).
Finally, given the relevance of EMT inmetastasis, we extended
our findings to an in vivo model. To this aim, we used a mouse
model of experimental metastasis that involves the tail injection
of MDA-MB-231 cells and the quantification of metastatic cells
that colonize the lungs. Since this is long-term protocol (2.5
months), we used a stable knockdown approach. Using the PLKO
system of lentiviral shRNA expression, we transducedMDA-MB-
231 cells with three different shRNAs against PKCα or ZEB1,
followed by selection with puromycin. Importantly, in MDA-
MB-231 cells subjected to stable PKCα depletion we observed
a concomitant downregulation of ZEB1 (Figures 5A,B), thus
recapitulating our findings using transient RNAi and PKC
inhibitors (see Figure 3 and Supplementary Figure 3). Along
the same line, ZEB1 stable depletion did not alter PKCα levels.
Notably, we found that the invasive capacity of MDA-MB-
231 cells was markedly reduced upon stable depletion of either
PKCα or ZEB1 (Figure 5C), as we previously observed with
RNAi and PKC pharmacological inhibitors (see Figure 4 and
Supplementary Figure 4).
For the experimental metastasis experiment we selected
the stable cell line with the strongest PKCα downregulation
(shRNAα2) and ZEB1 (shRNA#1). To precisely quantify
colonization of mouse lungs by the breast cancer cells, we used
a protocol were the ratio of Human/Mouse cells is determined
by q-PCR using primers for human and mouse GAPDH,
respectively (Human GAPDH /Mouse GAPDH) (Figure 5D).
Strikingly, we observed that PKCα downregulation impaired the
metastatic capacity of breast cancer cells, as we also observed
for ZEB1 knockdown (Figure 5D). Taken together, these findings
demonstrate that an axis comprising PKCα-ZEB1 modulates the
metastatic potential of breast cancer cells by promoting multiple
mesenchymal features during the progression of the disease.
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FIGURE 3 | PKCα silencing or inhibition downregulates ZEB1 levels. MDA-MB-231 (A), MDA-MB-453 and BT549 (B) cells were transfected with specific PKCα RNAi
duplexes (α1 and α2) or the non-target control RNAi (NTC). Western blot analysis for PKCs and EMT markers was carried out 72 h later. P, parental cells. Blue bar
graphics represent protein levels (fold-change) normalized to β-actin and relativized to the NTC. mRNA levels of PKCα, ZEB1, E-cadherin and vimentin (A) or PKCα
and ZEB1 (B) were assessed by RT-qPCR and results were plotted on the red bar graphics (fold-change) normalized to the housekeeping gene UBC and relativized to
NTC. (C) MDA-MB-231 cells were transfected with specific RNAi duplexes for ZEB1 (#1 and #2) or NTC RNAi. Western blot analysis for PKCs and EMT markers was
carried out 72 h later. The graphics (blue bars) represent the quantification (fold-change) normalized to β-actin and relativized to the NTC. PKCα and ZEB1 mRNA
levels were represented on the red bar graphics as fold-change, normalized to the UBC and relativized to the NTC. Results are expressed as mean ± S.D. ns, not
significant; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.
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FIGURE 4 | PKCα silencing recapitulates the EMT phenotypes associated with ZEB1 downregulation. (A) MDA-MB-231 cells were transfected with specific PKCα
RNAi duplexes (α1 and α2) or NTC RNAi for 72 h or treated with GF109203X (GF, 5µM) for 48 h. Migration was assessed using a wound healing assay. Graphics
represent the migrated area relativized to NTC or vehicle (V), respectively. (B) MDA-MB-231 cells were transfected with four different PKCα RNAi duplexes (α1, α2, α3,
and α4) or NTC RNAi, and invasion was assessed 72 h later. The images display representative fields of invading cells. Bar: 50µm. Graphs show the percentage of
invading cells per field relativized to the NTC. Results are expressed as mean ± S.D. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.
DISCUSSION
The activation of EMT has a documented role in promoting a
metastatic phenotype (8, 9). While EMT might be important in
essentially all types of cancers known to metastasize (4, 7, 9, 67),
it becomes particularly relevant in breast carcinomas. This is
due not only to their epithelial origin, but also to the fact that
in situ breast carcinomas do not pose a major life threat for
patients, in contrast to primary tumors on other body locations
such as the brain or other internal organs (68–70). In fact, the
transformation to an invasive state and the subsequent metastasis
and colonization of distal organs is the main cause of death in
breast cancer patients (68, 69, 71, 72).
In this work we have approached the question of how the
activity of the EMT transcription factor ZEB1 can be modulated
in breast cancer cells. Using an unbiased approach to find
phospho-sites in ZEB1, we identified a previously unknown
relationship between this transcription factor and PKCα, a kinase
widely implicated in tumorigenesis and metastasis (45, 48, 66).
PKCα Is a Key Regulator of ZEB1
Expression Levels in Breast Cancer Cells
Our study builds up on the central role of ZEB1 during the EMT
in mammary cells, being able to activate several EMT features
such as E-cadherin down-regulation and the acquisition of a
highly invasive phenotype required for metastasis. These findings
feed the current controversy of whether the EMT is dispensable
or indispensable for the metastatic phenotype of cancer cells
(10, 17, 72–74). The findings reported herein support the notion
that ZEB1 is an essential player of the metastatic phenotype in
breast cancer cells. Notably, a deletion mutant comprising only
10% of full length ZEB1 was sufficient to trigger a consistent EMT
activation in non-transformed NMuMG mammary epithelial
cells. This truncated protein is indeed heavily phosphorylated
by PKCs, as determined in silico and with an anti-phospho-PKC
substrate motif antibody.
A key finding of this study is that ZEB1 is highly expressed
in basal-like breast cancer cells, which are known to possess a
high metastatic potential (68, 69, 72). A strong correlation was
observed between ZEB1 and PKCα levels in breast cancer cells,
with a remarkable high expression of ZEB1 and PKCα in MDA-
MB-231 and BT-549 basal-like cells, which display a significant
degree of aggressiveness. The causality of this association was
further confirmed using PKCα silencing approaches, which
triggered a pronounced downregulation of ZEB1 in several breast
cancer cell lines. These findings not only unveil a previously
unforeseen regulatory pathway whereby PKCα controls ZEB1
expression levels, but also consolidates PKCα as a central player
in the EMT program. Such notion has been put forward before
by different lines of evidence. First, seminal work from the
Weinberg’s lab showed that transformation of normal mammary
cells induced by EMT transcription factors TWIST, SNAIL,
and SLUG triggers a consistent up-regulation of PKCα (48).
Second, PKCα overexpression in MCF-7 and T-47D cells was
found to promote anchorage-independent growth and the loss
of the epithelial phenotype (75, 76). More recently, PKCα has
been linked to elevated p120-catenin and claudin-1 levels (77),
two markers of activated EMT program. In addition, a recent
study reported that PKCα stabilizes TWIST1 expression (78).
Taken together, these results argue for a central role for PKCα
in the control of EMT by regulating of the expression of
transcription factors.
An outstanding question that remains to be addressed in
future studies is the relevance of the PKC-ZEB1 pathway in other
types of human cancers. Even though in this study we focused
on breast cancer due to our initial findings with a collection of
breast cancer cells (Figure 2), there is no reason to assume that a
similar scenario could not be observed in other types of cancers
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FIGURE 5 | PKCα is required for breast cancer cell metastasis. (A) Stable knockdown of PKCα (shα1, shα2, shα3) or ZEB1 (Z1, Z2, Z3) in MDA-MB-231 cells was
achieved using the PLKO lentiviral system. (B) Western blot analysis for EMT markers. (C) Invasiveness was assessed by the Matrigel invasion assay. Graphics
represent the number of invading cells per field relativized to NTC. (D) Scheme of the experimental metastasis assay in NOD/SCID mice. Seventy-five days after cell
injection, murine, and human levels of GAPDH were analyzed by RT-qPCR in mouse lungs. Graphs show the ratio of Human GAPDH /Mouse GAPDH relativized to
the NTC control. Results are expressed as mean ± S.D. **p ≤ 0.01; ***p ≤ 0.001.
as well. In fact, ZEB1 has been implicated in the promotion of
metastasis in other malignancies such as ovarian (79), gastric
(80), pancreatic (10, 81), and hepatocellular carcinoma (82).
Another important point to consider in future studies relates
to the nature of the underlying mechanism by which PKCα
regulates ZEB1 expression. Our results argue for the existence
of multiple mechanisms, which may not necessarily apply to
every breast cancer cell line. For instance, PKCα RNAi depletion
strongly reduced ZEB1 mRNA levels in MDA-MB-231 cells, but
to a lesser extent in BT-549 cells and MDA-MB-453 cells. These
differences may reflect different penetrance among cell types.
Nonetheless, database analysis revealed significant correlation
in a set of 54 breast cancer cell lines, suggestive of conserved
regulatory mechanisms among breast cancer cells at the mRNA
level. Our studies also suggest additional PKCα-regulated post-
transcriptional mechanisms that control ZEB1 protein stability,
which might not be mutually exclusive with those controlling
mRNA expression. Indeed, regulation of ZEB1 protein stability
via phosphorylation has been previously described, such as ATM-
mediated ZEB1 phosphorylation and upregulation in response
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to DNA damage (83). Other EMT transcription factors, such
as SNAIL and TWIST1, are also subject to phosphorylation-
mediated stabilization (42). The identification of the post-
translational mechanisms controlling ZEB1 stability is beyond
the goals of the present study. Since ZEB1 is subject to
ubiquitination (84), we speculate that PKCα may control ZEB1
stability via regulation of ubiquitin ligases or other components
of the proteasomal degradation machinery. Another intriguing
possibility is that the miR-200 family of microRNAs, which
has been linked to the expression control of both ZEB1 and
PKCα (18, 32, 85, 86) might play a role in the regulation of the
PKCα-ZEB1 axis.
Inhibition of the EMT as a Therapeutic
Strategy: A Potential Niche for PKC
Inhibitors?
The intuitive concept of targeting metastasis has been around in
the oncology field for a long time. However, in comparison
to classical cytotoxic therapies, target discovery for the
exclusive inhibition of metastasis is far behind (87). Metastatic
dissemination could be tackled at multiple steps, from the
detachment of the cancer cells from the primary tumor to the
nesting at distant sites (88). Herein, we provide compelling
evidence indicating that the inhibition of PKCα could be used
as a therapeutic strategy to impair breast cancer cell invasion
and metastasis. Based on our results, PKCα represents an
attractive approach to translate into a clinical setting. PKCα
inhibitors have been generated and assessed as anti-tumor agents
(46–48, 89–95). Moreover, pharmacological inhibition of PKCα
inhibits the growth of xenografts derived from triple-negative
breast cancer patients, which express high PKCα levels, but also
selectively target cells that have undergone EMT, which are also
enriched for stem cell properties (48). Taken together, it would
be interesting to thoroughly assess the use of selective PKCα
inhibitors as anti-cancer agents in triple-negative breast cancer.
Our results also highlight the potential of repositioning PKCα
inhibitors for their use as antimetastatic agents.
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